I'm LongbridgeAI, I can summarize articles.ADARx Pharmaceuticals, a late-stage biotech developing siRNA therapeutics, filed for an IPO on the Nasdaq Global Market under ticker 'ADRX'. Proceeds will fund clinical programs for complement-mediated diseases, hereditary angioedema, thrombotic disease, obesity, and neurodegeneration. The company utilizes proprietary MST and CTD platforms and has a collaboration with AbbVie.
ADARx Pharmaceuticals, a late-clinical stage biotechnology company focused on next‑generation siRNA therapeutics, filed for an initial public offering. The company plans to list on the Nasdaq Global Market under the ticker "ADRX." Proceeds will support multiple clinical programs, including complement-mediated diseases, hereditary angioedema, thrombotic disease, obesity and neurodegeneration.
Business Description
ADARx Pharmaceuticals is a biotechnology company developing next‑generation small interfering RNA (siRNA) medicines designed for deep, durable, and selective gene silencing. The company’s proprietary MST (messenger RNA Silencing Technology) optimizes siRNA sequence and chemistry for potency and durability, while its CTD (Cell Targeted Delivery) platform enables targeted delivery to hepatic and extrahepatic tissues, including adipose and neurons. ADARx’s wholly owned pipeline includes three clinical programs—agazisiran (CFB) for complement‑mediated diseases, onvuzosiran (PKK) for hereditary angioedema with FDA Fast Track and orphan designation, and ADX‑626 (FXI) for secondary stroke prevention—and two advanced preclinical programs: ADX‑077 for obesity and ADX‑199 targeting APP in neurons for neurodegenerative diseases.
The company has demonstrated program‑to‑program clinical consistency with potent and durable target knockdown, supporting infrequent dosing intervals (e.g., quarterly to semi‑annual). Beyond its core programs, ADARx is expanding into additional tissues such as microglia, skeletal muscle, cardiac muscle and ocular tissues, and is advancing bispecific-siRNA designs. A discovery‑stage collaboration with AbbVie adds non‑dilutive capital and validation to its platform, positioning ADARx to scale pipeline development across multiple therapeutic areas.
Market Overview
- Total addressable market: IgAN therapies projected at $12.21 billion globally by 2032.
- Market growth: PNH therapies estimated at $5.57 billion by 2032; dry AMD/GA market around $10 billion and dry AMD drugs projected at $4.7 billion by 2032.
- Market position: Pipeline-in-a-product potential in complement diseases; advancing extrahepatic delivery to adipose and neurons.
- Key competitors: Alnylam, Ionis, Arrowhead, Novartis, Regeneron, Takeda, Vera, Vertex, Astellas, Biogen, Roche, AstraZeneca, Eli Lilly, Novo Nordisk, Wave Life Sciences, among others.
- Industry trends: Rising clinical validation of siRNA; increasing interest in Factor XI inhibition; expansion of siRNA beyond liver via targeted delivery; strong investment and partnering momentum.
Operational Metrics
- Customers: Not applicable; development-stage biotech.
- Locations: Headquarters at 5871 Oberlin Drive, Suite 200, San Diego, California 92121.
- Geographic presence: Global clinical development with trials in the U.S., China and other regions.
- Partnerships: AbbVie collaboration with $335 million upfront, up to $385 million in option payments and up to $7.45 billion in milestones, plus tiered royalties.
- Orders/GMV: Not applicable.
- Other key metrics: 100 full-time employees as of June 30, 2026; onvuzosiran Fast Track and orphan drug designation; neuron-targeted delivery demonstrated in NHPs; Phase 3 STOP-HAE topline data expected by end of 2027.
Financials Highlights
- Revenue (current): $3.45 million (2025, collaboration)
- Revenue growth: From $0 in 2024 to $3.45 million in 2025, driven by AbbVie collaboration revenue recognition
- Operating income: Loss from operations: $(88.37) million (2025)
- Net income: Net loss: $(73.09) million (2025)
Management
- Zhen Li, Ph.D., President and Chief Executive Officer - Co-founder; former SVP at Arrowhead Pharmaceuticals and Director at Merck with extensive oligonucleotide R&D and delivery platform leadership.
- Ryan Fisk, M.B.A., Chief Financial Officer and Chief Business Officer - Over 20 years in healthcare investment banking; former Managing Director at Goldman Sachs.
- A. Robert MacLeod, Ph.D., Chief Scientific Officer - 25+ years in drug discovery; former VP and Franchise Head of Oncology at Ionis; advanced 15+ drug candidates.
- Rui Zhu, Ph.D., Chief Technology Officer - Co-founder; previously at Arrowhead as key inventor and co-lead of multiple siRNA programs including an FDA‑approved product.
IPO Structure
- Issuer: ADARx Pharmaceuticals, Inc.
- Filing date: September 04, 2026
- Proposed ticker: ADRX
- Exchange: Nasdaq Global Market
- Lead underwriters: J.P. Morgan; Morgan Stanley; TD Cowen; UBS Investment Bank; LifeSci Capital
- Use of proceeds: Advance Phase 2 and potential Phase 3 for agazisiran; complete Phase 3 STOP-HAE and support pre-commercial work for onvuzosiran; complete Phase 1a and initiate Phase 2 for ADX-626; initiate Phase 1 for ADX-077 and ADX-199; plus additional R&D, working capital and general corporate purposes.
Original SEC Filing: ADARx Pharmaceuticals, Inc. - S-1 - Sep. 04, 2026